On March 13, 2025, Opus Genetics, Inc. announced that its independent Board members approved equity awards for two new employees. These awards were granted under the company's 2021 Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards consisted of options to purchase an aggregate of 205,742 shares of the company's common stock. The options have an exercise price of $0.93 per share, which was the closing price on the grant date.
These options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly or quarterly installments thereafter, contingent on continued service.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.